Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

ClinicalTrials.gov ID: NCT00078858

Public ClinicalTrials.gov record NCT00078858. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 21, 2026, 12:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial

Study identification

NCT ID: NCT00078858
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Fred Hutchinson Cancer Center; Other
Enrollment: 37 participants

Conditions and interventions

Conditions

Interventions

cyclosporine Drug
fludarabine phosphate Drug
laboratory biomarker analysis Other
mycophenolate mofetil Drug
nonmyeloablative allogeneic hematopoietic stem cell transplantation Procedure
peripheral blood stem cell transplantation Procedure
total-body irradiation Radiation

Drug · Other · Procedure + 1 more

Eligibility (public fields only)

Age range: Not listed
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 31, 2003
Primary completion: Dec 31, 2005
Completion: Not listed
Last update posted: Jan 17, 2020

Started 2003

United States locations

U.S. sites: 7
U.S. states: 7
U.S. cities: 7

Facility	City	State	ZIP	Site status
Stanford University Hospitals and Clinics	Stanford	California	94305	—
Rocky Mountain Cancer Centers-Midtown	Denver	Colorado	80218	—
Emory University/Winship Cancer Institute	Atlanta	Georgia	30322	—
OHSU Knight Cancer Institute	Portland	Oregon	97239	—
Huntsman Cancer Institute/University of Utah	Salt Lake City	Utah	84112	—
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium	Seattle	Washington	98109	—
Froedtert Memorial Lutheran Hospital, Medical College of Wisconsin	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00078858, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 17, 2020 · Synced May 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00078858 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →